IPO’s Comments to China’s NMPA on the “Implementation Measures for the Protection of Drug Trial Data” and the “Working Procedures for the Protection of Drug Trial Data.”
IPO’s Comments to China’s NMPA on the "Implementation Measures for [...]
IPO’s Comments to China’s NMPA on the "Implementation Measures for [...]
IPO Comments to Indian Patent Office on Draft Guidelines for [...]
IPO Comments on “Artificial Intelligence Action Plan”
IPO Post-Hearing Statement to Special 301 Subcommittee
IPO Letter to Secretary of Commerce Howard Lutnick
Joint IPO and AIPLA Letter to Senate Committee on Commerce, [...]
IPO’s Notice of Intent to Testify and Hearing Statement re: [...]
IPO 2025 Special 301 Review Comments
IPO Comments to Legislative Affairs Commission of the Standing Committee [...]
ADAPT & IPO’s Practical Guide on Allyship, Mentorship, and Sponsorship